单夜夜间氧疗对高原阻塞性睡眠呼吸暂停患者的影响:随机交叉试验
结果显示NOS使总AHI中位数下降17.9/h(95%CI 8.0/h-27.1/h,P<.001),夜间血氧饱和度(Spo2)提高7.0%(95%CI 6.0%-8.0%,P<.001),并降低睡眠心率和晨脉率,但主观睡眠质量与认知表现无变化。
要点
- 单夜2 L/min夜间氧疗可显著降低高原OSA患者的总AHI和阻塞性AHI,并提高Spo2。
- NOS降低睡眠心率和晨起脉率,但主观睡眠质量和认知表现未见改变。
- 对无法耐受CPAP的高原OSA患者,NOS可能是潜在治疗选择,尚需长期研究验证。
核心结论
- 在海拔3,200米的高原OSA患者中,单夜夜间氧疗显著改善睡眠相关呼吸紊乱和夜间氧合,并降低睡眠心率与晨脉率。
- 若这些获益在更长期研究中得到证实,NOS或可作为无法接受CPAP治疗的高原OSA患者的治疗选择。
研究设计与样本
- 患者随机接受鼻导管夜间氧疗与假氧(环境空气)各一晚,流量2 L/min,两阶段间隔2周洗脱期,治疗夜行多导睡眠监测,次晨评估其他结局。
- 主要结局为夜间氧疗夜与假氧夜之间呼吸暂停低通气指数(AHI)的差异。
主要发现
- 假氧夜总AHI中位数为43.4/h(31.1/h-67.5/h),阻塞性AHI为41.9/h(28.5/h-66.8/h),中枢性AHI为0.6/h(0.1/h-1.3/h),脉搏血氧测定Spo2为87.0%(84.5%-89.0%)。
- 意向性治疗分析中,NOS使总AHI中位数下降17.9/h(95%CI 8.0/h-27.1/h,P<.001),其中阻塞性AHI下降16.0/h(95%CI 6.8/h-26.0/h,P<.001),中枢性AHI下降0.4/h(95%CI 0.1/h-0.9/h,P<.001)。
- NOS使Spo2提高7.0%(95%CI 6.0%-8.0%,P<.001),睡眠心率和晨起脉率显著降低,主观睡眠质量与认知表现无变化。
临床怎么用
- 对居住于3,200米高原、无法接受CPAP治疗的OSA患者,可考虑试用夜间氧疗以改善夜间呼吸紊乱与氧合。
- 夜间氧疗的认知与主观睡眠质量获益未获证实,临床决策应结合长期疗效证据。
局限性
- 研究仅评估单夜夜间氧疗,缺乏长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment of OSA in highland residents is not established. RESEARCH QUESTIONS: Does nocturnal oxygen supplementation (NOS) improve sleep-related breathing disturbances, nocturnal oxygenation, and cognitive performance in patients with OSA living at 3,200 m? STUDY DESIGN AND METHODS: Forty patients with OSA permanently living in Shangri-La, China at 3,200 m (median age [interquartile range], 47.0 [44.0-53.0] years; oxygen desaturation index, 38.4/h [34.2/h-52.3/h]), were randomly assigned to receive nasal NOS and sham oxygen (ambient air), for one night each, at 2 L/min, in a crossover design, separated by a washout period of 2 weeks. During treatment nights polysomnography was performed, and further outcomes were evaluated the next morning. The primary outcome was the difference in apnea-hypopnea index (AHI) between nights with NOS and nights with sham oxygen. RESULTS: During nights with sham oxygen, the median (interquartile range) total AHI was 43.4/h (31.1/h-67.5/h), the obstructive AHI was 41.9/h (28.5/h-66.8/h), and the central AHI was 0.6/h (0.1/h-1.3/h); blood oxygenation as determined by pulse oximetry (Spo2) was 87.0% (84.5%-89.0%). In intention-to-treat analysis, NOS decreased the total AHI by a median of 17.9/h (95% CI, 8.0/h-27.1/h; P < .001), through a reduction in obstructive AHI by 16.0/h (95% CI, 6.8/h-26.0/h; P < .001) and central AHI by 0.4/h (95% CI, 0.1/h-0.9/h; P < .001). NOS also increased Spo2 by 7.0% (95% CI, 6.0%-8.0%; P < .001). Heart rate during sleep and pulse rate in the morning after NOS were significantly reduced, but subjective sleep quality and cognitive performance showed no changes. INTERPRETATION: In highland residents with OSA, NOS significantly improved sleep-related breathing disturbances and nocturnal oxygenation. NOS also reduced heart rate during sleep and morning pulse rate. If these beneficial effects are confirmed in longer term studies, NOS may be a treatment option for highland patients with OSA who cannot be treated by CPAP. TRIAL REGISTRY: Chinese Clinical Trial Registry; No.: ChiCTR1800017715; URL: http://www.chictr.org.cn/showproj.aspx?proj=29768.
引用
- Tan L, Li T, Zhang Y, et al. Effect of One Night of Nocturnal Oxygen Supplementation on Highland Patients With OSA: A Randomized, Crossover Trial. Chest. 2021. PMID: 33667495. doi:10.1016/j.chest.2021.02.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。